Our Path to a Cure

Change-makers for more than 15 years, and we’re just getting started.

Colorectal cancer is the second-leading cause of cancer death. By 2030, it’s expected to become the leading cause of cancer death for those under 49. Yet, it’s the cancer no one wants to talk about. Fight CRC works to support and inform patients while driving policy change and breakthrough research.

Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause. Together, with our community of patients, families, and caregivers, we work relentlessly to bring attention to colorectal cancer and all the issues surrounding it.

The overall survival rate for people with colorectal cancer has not budged, and the treatment pipeline has stagnated. We need to re-evaluate how we look at overall survival and begin to look beyond only “stage of colorectal cancer.” We need to adjust narrow goals of targeted therapies for specific demographics: We need to push the science.

Be a Research Champion!

Together we can show our policymakers the caliber of organizations vested in Path to a Cure efforts. Join us.

This report reflects the commitment of advocates across the country involved in the scientific research process and locking arms to advocate for colorectal cancer research funding, and communicating research findings to the public. We represent passionate men and women willing to push for policy change and move past the status quo. For our patients, we continue to fight for them and alongside thtem. We are giving a voice to all those impacted by colorectal cancer. We bravely hold on to hope for a cure.

“The Path to a Cure report is the first of its kind, pushing us to collaborate and align our efforts in all areas of colorectal cancer.”

Anjee Davis, MPPA, President, Fight CRC

The Path to a Cure report is broken down into four sections. Each section in the report provides progress indicators, key messages, opportunities and challenges, and the voices of survivors. Each indicator has a plan of action to ensure that all partners, collaborators, and champions play a role in contributing a path to a cure.

Biology and Etiology

Prevention and Early Detection

Treatment

Survivorship and Recurrence

Think Tank Events

Together, working hand in hand across industry, academia, advocacy, public health, government agencies, and with patients, this plan will drive and unify stakeholders to ask important questions, prioritize, and expand our scientific efforts. 

https://youtu.be/kY_AZoBbQAA

"Individuals with stage IV cancer face the worst kind of deadline: The deadline that their advanced disease is going to someday take their life if we don’t make greater advances.”

–Dr. Rich Goldberg, Board Member & GI Oncologist

Meet the Experts Behind this Report

We express our deepest appreciation to all those who provided time, effort, and expertise in their contributions, discussions, and evolution of this report. A special thanks to our advisors and writers, for their contributions in stimulating suggestions, encouragement, and vision in the efforts to save lives from colorectal cancer. 

Path to a Cure report continues to engage the conversation around patient education and awareness, communication with your health care provider–especially around an extremely uncomfortable topic, family history, and systems and practices–and how we align incentives with what is actually best for everyone.

The Experts
  • Al Benson, MD | Northwestern University
  • Yin Cao, ScD, MPH | Washington University School of Medicine in St. Louis
  • Anjee Davis, MPPA | Fight Colorectal Cancer
  • Dustin Deming, MD | University of Wisconsin Carbone Cancer Center
  • Andrea (Andi) Dwyer | University of Colorado Cancer Center
  • Ashley Glode, PharmD | University of Colorado
  • Richard Goldberg, MD | West Virginia University Cancer Institute
  • Samir Gupta, MD | University of California, San Diego
  • Heather Hampel, MS, LGC | Ohio State University Comprehensive Cancer Center
  • Chris Heery, MD | Precision BioSciences
  • Rishi Jain, MD | Fox Chase Cancer Center
  • Sheetal Kircher, MD | Northwestern University
  • Jennifer Kolb, MD | VA Greater Los Angeles Health Care System
  • Scott Kopetz, MD * | MD Anderson
  • Smitha Krishnamurthi, MD | University of Texas Southwestern
  • Dung Le, MD | Johns Hopkins Medical Center
  • Chris Lieu, MD | University of Colorado Cancer Center
  • Fola May, MD, PhD | University of California, Los Angeles
  • Noel de Miranda, PhD | Leiden University
  • Caitlin Murphy, PhD, MPH | University of Texas Southwestern
  • Linda Overholser, MD, MPH | University of Colorado Cancer Center
  • Michael Overman, MD | MD Anderson
  • Swati Patel, MD | University of Colorado
  • José Perea, MD | Fundación Jiménez Díaz University Hospital
  • Nicholas Petrelli, MD, FACS | Christiana Care Health System
  • Leonard Saltz, MD | Memorial Sloan Kettering Cancer Center
  • Nina Sanford, MD | UT Southwestern
  • Cynthia Sears, MD | Johns Hopkins University
  • Rebecca Seigel, MPH | American Cancer Society
  • Robert Smith, PhD | American Cancer Society
  • Peter Stanich, MD | Ohio State University
  • Joel E Tepper, MD | University of North Carolina School of Medicine
  • Erin Van Blarigan, ScD | University of California, San Francisco
  • Jennifer Weiss, MD, MS | University of Wisconsin
  • Karen Wheling | Survivor Advocate
  • Ann Zauber, PhD | Memorial Sloan Kettering Cancer Center

*Chair of Fight CRC’s Path to a Cure Think Tank on December 3rd, 2021.

Our Path to a Cure is Supported by